Skip to main content

Articles

Page 94 of 108

  1. Progestins are included in menopausal hormone replacement therapy to counteract the increased risk for endometrial cancer associated with estrogen replacement therapy. Studies of hormone replacement therapy an...

    Authors: Catherine Schairer
    Citation: Breast Cancer Research 2002 4:244
  2. Tamoxifen is probably the most important drug in the history of the management of breast cancer and its development is a tribute to cross talk between laboratory scientists and clinical investigators. Its use ...

    Authors: Michael Baum
    Citation: Breast Cancer Research 2002 4:213
  3. The 2002 British Cancer Research Meeting was held from 30th June to 3rd July in Glasgow, UK. The meeting was structured to include educational workshops, plenary lectures, symposia, and poster sessions, which ...

    Authors: Alicia T Parkes and Valerie Speirs
    Citation: Breast Cancer Research 2002 4:202
  4. A relatively small number of cells in the normal human mammary gland express receptors for oestrogen and progesterone (ER and PR), and there is almost complete dissociation between steroid receptor expression ...

    Authors: Elizabeth Anderson
    Citation: Breast Cancer Research 2002 4:197
  5. The progesterone receptor knockout mouse demonstrated progesterone's importance to parity-induced mammary tertiary branching and lobuloalveologenesis. Because early parity provides significant protection again...

    Authors: Selma Soyal, Preeti M Ismail, Jie Li, Biserka Mulac-Jericevic, Orla M Conneely and John P Lydon
    Citation: Breast Cancer Research 2002 4:191
  6. Progesterone is an essential regulator of normal female reproductive function. Its effects are mediated by two nuclear progesterone receptor (PR) proteins, PRA and PRB, which are identical except for an additi...

    Authors: J Dinny Graham and Christine L Clarke
    Citation: Breast Cancer Research 2002 4:187
  7. Progesterone, an ovarian steroid hormone, plays a key role in the development and function of the mammary gland, as it also does in the uterus and the ovary. The action of progesterone is mediated through its ...

    Authors: Xiuhua Gao and Zafar Nawaz
    Citation: Breast Cancer Research 2002 4:182
  8. A recent analysis by the Collaborative Group on Hormonal Factors in Breast Cancer has provided the most precise quantification to date of the familial risks of breast cancer. The familial relative risks are sh...

    Authors: Douglas F Easton
    Citation: Breast Cancer Research 2002 4:179
  9. The transcription factor NF-κB exhibits altered activity in some breast cancers but the relevance of this association has not been established. Cao et al.'s elegant study recently published in Cell reveals a NF-κ...

    Authors: Richard Clarkson
    Citation: Breast Cancer Research 2002 4:173
  10. Iranian breast cancer patients are relatively younger than their Western counterparts. The objective of the present study was to investigate risk factors for breast cancer in Iranian women.

    Authors: Mandana Ebrahimi, Mariam Vahdaninia and Ali Montazeri
    Citation: Breast Cancer Research 2002 4:R10
  11. The objective of the present study was to examine the prognostic and predictive significance of the apoptosis-related marker Fas ligand (FasL):Fas ratio in breast cancer.

    Authors: Toralf Reimer, Dirk Koczan, Heiner Müller, Klaus Friese, Hans-Jürgen Thiesen and Bernd Gerber
    Citation: Breast Cancer Research 2002 4:R9
  12. Epithelial/mesenchymal cell interactions are necessary for proper ductal morphogenesis throughout all stages of mammary gland development. Besides the well-established stromal components, such as adipocytes an...

    Authors: Valérie Gouon-Evans, Elaine Y Lin and Jeffrey W Pollard
    Citation: Breast Cancer Research 2002 4:155
  13. Cyclin E, a key mediator of entry into the cell division cycle, is expressed abundantly in many breast cancers. However, amplification of the cognate gene is observed rarely, leaving the responsible mechanism(...

    Authors: Greg H Enders
    Citation: Breast Cancer Research 2002 4:145
  14. Recent reports detailing the expression profiles of primary breast cancer have pointed to the utility of this approach in defining subclasses with distinct molecular configurations and clinical behaviour. Some...

    Authors: Edison T Liu and Christos Sotiriou
    Citation: Breast Cancer Research 2002 4:141
  15. High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen. Subsequently, the use of estrogen was largely aba...

    Authors: James N Ingle
    Citation: Breast Cancer Research 2002 4:133
  16. Breast cancer is hormone related, as are cancers of the endometrium, ovary, and prostate. Several studies have suggested that higher extracellular levels of androgens are associated with breast cancer risk, wh...

    Authors: Chunxia Yang, Nobuyuki Hamajima, Hiroji Iwata, Toshiko Saito, Keitaro Matsuo, Kaoru Hirose, Manami Inoue, Toshiro Takezaki and Kazuo Tajima
    Citation: Breast Cancer Research 2002 4:R8
  17. Breast cancer is the most common female malignancy and a major cause of death in middle-aged women. So far, germline mutations in the BRCA1 and BRCA2 genes in patients with early-onset breast and/or ovarian cance...

    Authors: Vahid R Yassaee, Sirous Zeinali, Iraj Harirchi, Soghra Jarvandi, Mohammad A Mohagheghi, David P Hornby and Ann Dalton
    Citation: Breast Cancer Research 2002 4:R6

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions